Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.

The PI3K (phosphatidylinositol-3-kinase)/mTOR (mammalian target of rapamycin) pathway is frequently activated in endometrial cancer through various PI3K/AKT-activating genetic alterations. We examined the antitumor effect of NVP-BEZ235--a dual PI3K/mTOR inhibitor--and RAD001--an mTOR inhibitor--in 1...

Descrición completa

Detalles Bibliográficos

Principais autores:	Keiko Shoji, Katsutoshi Oda, Tomoko Kashiyama, Yuji Ikeda, Shunsuke Nakagawa, Kenbun Sone, Yuichiro Miyamoto, Haruko Hiraike, Michihiro Tanikawa, Aki Miyasaka, Takahiro Koso, Yoko Matsumoto, Osamu Wada-Hiraike, Kei Kawana, Hiroyuki Kuramoto, Frank McCormick, Hiroyuki Aburatani, Tetsu Yano, Shiro Kozuma, Yuji Taketani
Formato:	Artigo
Idioma:	Inglês
Publicado:	Public Library of Science (PLoS) 2012-01-01
Series:	PLoS ONE
Acceso en liña:	https://doi.org/10.1371/journal.pone.0037431
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!